NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $162,000 | -60.1% | 30,062 | 0.0% | 0.00% | -57.1% |
| Q4 2021 | $406,000 | -24.8% | 30,062 | 0.0% | 0.01% | -30.0% |
| Q3 2021 | $540,000 | +4.7% | 30,062 | 0.0% | 0.01% | +11.1% |
| Q2 2021 | $516,000 | -14.1% | 30,062 | 0.0% | 0.01% | -10.0% |
| Q1 2021 | $601,000 | +280.4% | 30,062 | +539.6% | 0.01% | +233.3% |
| Q1 2019 | $158,000 | -64.2% | 4,700 | -50.0% | 0.00% | -40.0% |
| Q4 2018 | $441,000 | +53.7% | 9,400 | +100.0% | 0.01% | -16.7% |
| Q3 2018 | $287,000 | +15.3% | 4,700 | -7.8% | 0.01% | +20.0% |
| Q2 2018 | $249,000 | – | 5,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |